Literature DB >> 15755990

Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response.

Roman Ivanov1, Tineke Aarts, Samantha Hol, Angeline Doornenbal, Anton Hagenbeek, Eefke Petersen, Saskia Ebeling.   

Abstract

PURPOSE: The superior graft-versus-leukemia (GVL) effect of the female-to-male stem cell transplantation is partially independent from the concomitant graft-versus-host reactivity. However, the antigenic basis of this selective GVL response remains enigmatic, because no H-Y antigens with hematopoietic-restricted expression were identified. In this study, we report a novel H-Y epitope that is preferentially recognized on activated proliferating lymphocytes. EXPERIMENTAL
DESIGN: We generated a CTL clone YKIII.8 that showed reactivity toward male B*5201+ CD40-activated B cells, EBV-lymphoblastoid cell lines, and phytohemagglutinin-activated T-cell blasts but little or no reactivity toward fibroblasts, CD14+ cells, or unstimulated B and T cells. The antigen recognized by YKIII.8 was identified by screening of a cDNA expression library, and its pattern of expression was investigated.
RESULTS: cDNA of the male isoform of 40S ribosomal protein S4 was found to encode the antigenic peptide TIRYPDPVI, which was recognized by YKIII.8. Western blot analysis showed that rapidly proliferating cells overexpress the RPS4 protein in comparison with nonrecognized cell subsets. Retroviral transfer of YKIII.8 T-cell receptor resulted in preservation of the lymphoblast-specific reactivity pattern.
CONCLUSION: Our findings suggest that CTL specific to certain epitopes of ubiquitously expressed H-Y antigens may specifically target lymphoblasts, contributing to the selective GVL effect of female-to-male stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755990     DOI: 10.1158/1078-0432.CCR-04-1772

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Minor histocompatibility antigens are expressed in syncytiotrophoblast and trophoblast debris: implications for maternal alloreactivity to the fetus.

Authors:  Olivia J Holland; Caitlin Linscheid; Herbert C Hodes; Traci L Nauser; Melissa Gilliam; Peter Stone; Larry W Chamley; Margaret G Petroff
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

2.  T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.

Authors:  R Ivanov; S Hol; T I Aarts; A Hagenbeek; S B Ebeling
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

Review 4.  Clinical impact of H-Y alloimmunity.

Authors:  Rakesh Popli; Bita Sahaf; Hideki Nakasone; Joyce Yeuk Yu Lee; David B Miklos
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 5.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

6.  Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.

Authors:  Steven A McCarroll; James E Bradner; Hannu Turpeinen; Liisa Volin; Paul J Martin; Shannon D Chilewski; Joseph H Antin; Stephanie J Lee; Tapani Ruutu; Barry Storer; Edus H Warren; Bo Zhang; Lue Ping Zhao; David Ginsburg; Robert J Soiffer; Jukka Partanen; John A Hansen; Jerome Ritz; Aarno Palotie; David Altshuler
Journal:  Nat Genet       Date:  2009-12       Impact factor: 38.330

7.  DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.

Authors:  Kellie V Rosinski; Nobuharu Fujii; Jeffrey K Mito; Kevin K W Koo; Suzanne M Xuereb; Olga Sala-Torra; James S Gibbs; Jerald P Radich; Yoshiki Akatsuka; Benoît J Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2008-02-25       Impact factor: 22.113

Review 8.  Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy.

Authors:  Caitlin Linscheid; Margaret G Petroff
Journal:  Am J Reprod Immunol       Date:  2013-02-08       Impact factor: 3.886

9.  Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Authors:  R Oostvogels; M C Minnema; M van Elk; R M Spaapen; G D te Raa; B Giovannone; A Buijs; D van Baarle; A P Kater; M Griffioen; E Spierings; H M Lokhorst; T Mutis
Journal:  Leukemia       Date:  2012-10-01       Impact factor: 11.528

10.  Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors.

Authors:  Monika Dzierzak-Mietla; M Markiewicz; Urszula Siekiera; Sylwia Mizia; Anna Koclega; Patrycja Zielinska; Malgorzata Sobczyk-Kruszelnicka; Slawomira Kyrcz-Krzemien
Journal:  Bone Marrow Res       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.